Tracleer (bosentan), the first ORAL drug approved for pulmonary arterial hypertension

Actelion Pharmaceuticals is now promoting Tracleer (bosentan), the first ORAL drug approved for pulmonary arterial hypertension.

Pulmonary arterial hypertension is a rare but deadly disorder. It often leads to heart failure and death within 3 years.

Usual treatments include anticoagulants...calcium channel blockers...continuous IV infusions of Flolan (epoprostenol)...or surgery.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote